Published in Oncotarget on March 15, 2016
Attenuation of cancer-initiating cells stemness properties by abrogating S100A4 calcium binding ability in head and neck cancers. Oncotarget (2016) 0.75
MET expression during prostate cancer progression. Oncotarget (2016) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Antibody validation. Biotechniques (2010) 4.42
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol (2005) 4.16
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol (1997) 2.43
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol (2010) 1.96
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.70
The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol (2007) 1.67
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
c-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem (2007) 1.52
Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol (2008) 1.48
Targeted therapies in squamous cell carcinoma of the head and neck. Cancer (2009) 1.27
Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis (2009) 1.26
c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res (2006) 1.22
Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol (2014) 1.21
Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest (2007) 1.20
Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck (2010) 1.19
Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol Cell Biol (2004) 1.09
Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer (2006) 1.07
Promising new molecular targeted therapies in head and neck cancer. Drugs (2013) 1.07
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol (2009) 1.06
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell (2009) 1.06
Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ (2006) 1.05
Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res (2006) 1.03
Cetuximab: its unique place in head and neck cancer treatment. Biologics (2013) 1.01
Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One (2011) 0.98
Biomarker validation and testing. Mol Oncol (2014) 0.97
c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck (2010) 0.95
HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci (2008) 0.95
Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med (2004) 0.94
Met degradation: more than one stone to shoot a receptor down. FASEB J (2012) 0.92
Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. Anticancer Res (2004) 0.91
HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med (2014) 0.87
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer (2012) 0.87
Clinical significance of lymphatic and blood vessel invasion in oral tongue squamous cell carcinomas. Oral Oncol (2011) 0.87
Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol (2012) 0.86
Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med (2010) 0.85
Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic (2012) 0.85
MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One (2014) 0.84
Prognosis: a variable parameter: dynamic prognostic modeling in head and neck squamous cell carcinoma. Head Neck (2011) 0.84
Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma. Korean J Pathol (2012) 0.83
Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review. Clin Med Insights Oncol (2015) 0.82
Molecular diagnosis of minimal residual disease in head and neck cancer patients. Cell Oncol (Dordr) (2012) 0.78
Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci (2010) 0.76
Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review. Cancer Med (2015) 0.90
Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2. Head Neck (2014) 0.86
Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer Med (2015) 0.80
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head Neck (2016) 0.79
Correlation of human papillomavirus status with apparent diffusion coefficient of diffusion-weighted MRI in head and neck squamous cell carcinomas. Head Neck (2015) 0.78
Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging (2017) 0.77
Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. Oncotarget (2016) 0.75
Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification. J Clin Pathol (2017) 0.75
Amplification and protein overexpression of cyclin D1: Predictor of occult nodal metastasis in early oral cancer. Head Neck (2016) 0.75